Wire · operational-macro
Biotech is back, with H1 progress smoothing glide path through end of year: Truist
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 September 2026 · Fusion42 review
Truist Securities reports that biotech is recovering strongly with rising M&A activity, returning venture capital, and easing regulatory risks, resulting in a positive outlook for the sector through the end of 2026. The S&P Biotech ETF rose 34% in the first half of the year, supported by $136 billion spent across 57 deals, already surpassing 2025's total.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The biotech sector's recovery signals renewed capital access and deal flow that you can tap into for partnership or exit opportunities. Expect a narrower margin for error in execution as momentum stabilises but regulatory relief opens doors.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics